Skip to main content

Advertisement

SpringerLink
Log in

Elevated serum TRAIL levels in scleroderma patients and its possible association with pulmonary involvement

  • Original Article
  • Published:
Clinical Rheumatology Aims and scope Submit manuscript

Abstract

Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) has been reported to be involved in the pathophysiology of some autoimmune diseases as systemic lupus erythematosus, ankylosing spondylitis, and multiple sclerosis. The aim of this study was to assess serum TRAIL concentration in systemic sclerosis (SSc) patients and to investigate its possible association with various disease parameters. Thirty SSc patients as well as 25 rheumatoid arthritis (RA) patients and 25 healthy volunteers were included in the present study. Organ system involvement in SSc patients was investigated. Pulmonary function tests as well as chest high-resolution computed tomography (HRCT) were done to detect pulmonary involvement in our patients. TRAIL concentrations were measured in the sera of SSc patients, RA patients and healthy controls by enzyme-linked immunosorbent assay. Mean serum TRAIL levels were significantly higher in SSc patients than in the control RA patients and in healthy controls (p < 0.001) while they were not significantly different between patients with diffuse cutaneous SSc and patients with limited cutaneous scleroderma. Serum TRAIL levels were significantly higher in SSc patients with pulmonary involvement and were significantly correlated with HRCT scores. Serum TRAIL levels are significantly elevated in SSc patients and are associated with SSc-associated pulmonary involvement denoting a possible role of TRAIL in the pathogenesis of SSc. Further studies may be needed to confirm these findings and the possible use of TRAIL in detection and possibly treatment of SSc-associated pulmonary disease.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. White B (1996) Immunopathogenesis of systemic sclerosis. Rheum Dis Clin North Am 22:695–708

    Article  PubMed  CAS  Google Scholar 

  2. Krammer PH (2000) CD95’s deadly mission in the immune system. Nature 407:789–795

    Article  PubMed  CAS  Google Scholar 

  3. King C, Ilic A, Koelsch K, Sarvetnick N (2004) Homeostatic expansion of T cells during immune insufficiency generates autoimmunity. Cell 117:265–277

    Article  PubMed  CAS  Google Scholar 

  4. Jelaska A, Korn JH (2000) Role of apoptosis and transforming growth factor beta 1 in fibroblast selection and activation in systemic sclerosis. Arthritis Rheum 43:2230

    Article  PubMed  CAS  Google Scholar 

  5. Wiley SR, Schooley K, Smolak PJ et al (1995) Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 3(6):673–682

    Article  PubMed  CAS  Google Scholar 

  6. Le Blanc HN, Ashkenazi A (2003) Apo 2L/TRAIL and its death decoy receptors. Cell Death Differ 10:66–75

    Article  Google Scholar 

  7. Jo M, Kim TH, Seol DW et al (2000) Apoptosis induced in normal human hepatocytes tumour necrosis factor-related apoptosis-inducing ligand. Nat Med 6(5):564–567

    Article  PubMed  CAS  Google Scholar 

  8. Nitsch R, Bechmann I, Deisz RA et al (2000) Human brain-cell death induced by tumour-necrosis factor-related apoptosis-inducing ligand (TRAIL). Lancet 356:827–828

    Article  PubMed  CAS  Google Scholar 

  9. Lub-de Hooge MN, de Vries EG, de Jong S, Bijl M (2005) Soluble TRAIL concentrations are raised in patients with systemic lupus erythematosus. Ann Rheum Dis 64:854–858

    Article  PubMed  CAS  Google Scholar 

  10. Zai-Xing Y, Yan L, Hao W, Ye Z et al (2008) Preliminary clinical measurement of the expression of TNF-related apoptosis inducing ligand in patients with ankylosing spondylitis. J Clin Lab Anal 22(2):138–145

    Article  PubMed  Google Scholar 

  11. Huang WX, Huang P, Gomes A, Hillert J (2000) Apoptosis mediators FasL and TRAIL are upregulated in peripheral blood mononuclear cells in MS. Neurology 55:928–934

    Article  PubMed  CAS  Google Scholar 

  12. Preliminary criteria for the classification of systemic sclerosis (scleroderma): Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and therapeutic Criteria Committee (1980) Arthritis Rheum 23:581–590

    Article  Google Scholar 

  13. Le Roy EC, Black C, Fleischmajer R et al (1988) Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 15:202–205

    Google Scholar 

  14. Arnett FC, Edworthy SM, Bloch DA et al (1988) The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31:315–324

    Article  PubMed  CAS  Google Scholar 

  15. Clements PJ, Lachenbruch PA, Seibold JR et al (1993) Skin thickness score in systemic sclerosis: an assessment of interobserver variability in 3 independent studies. J Rheumatol 20:1892–1896

    PubMed  CAS  Google Scholar 

  16. Warrick JH, Bhalla M, Schabel SI, Silver RM (1991) High resolution computed tomography in early scleroderma lung disease. J Rheumatol 18:1520–1528

    PubMed  CAS  Google Scholar 

  17. Valat C, Diot E, Diot P (1998) Serum III procollagen is predictive of lung involvement in systemic sclerosis, but not serum I procollagen. Clin Exp Rheumatol 16:517–518

    PubMed  CAS  Google Scholar 

  18. Martin SJ, Grenn DR, Cotter TG (1994) Dicing with death: dissecting the components of the apoptosis machinery. Trends Biochem Sci 19:26–29

    Article  PubMed  CAS  Google Scholar 

  19. Kessel A, Rosner I, Rozenbaum M et al (2004) Increased CD8+ T cell apoptosis in scleroderma is associated with low levels of NF-kappa B. J Clin Immunol 24:30–36

    Article  PubMed  CAS  Google Scholar 

  20. Tsai HF, Lai JJ, Chou AH et al (2004) Induction of costimulation of human CD4 T cells by tumor necrosis factor-related apoptosis-inducing ligand: possible role in T cell activation in systemic lupus erythematosus. Arthritis Rheum 50(2):629–639

    Article  PubMed  CAS  Google Scholar 

  21. Matsumura R, Umemiya K, Kagami M et al (2002) Expression of TNF-related apoptosis inducing ligand (TRAIL) on infiltrating cells and of TRAIL receptors on salivary glands in patients with Sjogren’s syndrome. Clin Exp Rheumatol 20:791–798

    PubMed  CAS  Google Scholar 

  22. Kaplan MJ, Lewis EE, Shelden EA et al (2002) The apoptotic ligands TRAIL, TWEAK, and Fas ligand mediate monocyte death induced by autologous lupus T cells. J Immunol 169:6020–6029

    PubMed  CAS  Google Scholar 

  23. Rus V, Atamas SP, Shustova V et al (2002) Expression of cytokine- and chemokine-related genes in peripheral blood mononuclear cells from lupus patients by cDNA array. Clin Immunol 102:283–290

    Article  PubMed  CAS  Google Scholar 

  24. Matsuyama W, Yamamoto M, Higashimoto I et al (2004) TNF related apoptosis inducing ligand is involved in neutropenia of systemic lupus erythematosus. Blood 104:184–191

    Article  PubMed  CAS  Google Scholar 

  25. Yurovsky VV (2004) Cross-talk between TRAIL and TGF-β in regulation of collagen production in scleroderma lung disease. Arthritis Res Ther 6(Suppl 1):26

    Article  Google Scholar 

  26. Diot E, Boissinot E, Asquier E et al (1998) Relationship between abnormalities on high resolution computed tomography and pulmonary function in systemic sclerosis. Chest 114:1623–1629

    Article  PubMed  CAS  Google Scholar 

  27. Bouros D, Wells AU, Nicholson AG et al (2002) Histopathologic subset of fibrosing alveolitis in patients with systemic sclerosis and their relationship to outcome. Am J Respir Crit Care Med 165:1581–1586

    Article  PubMed  Google Scholar 

  28. Tomasek JJ, Gabbiani G, Hinz B et al (2002) Myofibroblasts and mechano-regulation of connective tissue remodeling. Nat Rev Mol Cell Biol 3:349–363

    Article  PubMed  CAS  Google Scholar 

  29. Harrison NK, Myers AR, Corrin B et al (1991) Structural features of interstitial lung disease in systemic sclerosis. Am Rev Respir Dis 144(3 Pt 1):706–713

    Article  PubMed  CAS  Google Scholar 

  30. Yurovsky VV (2003) Tumor necrosis factor-related apoptosis-inducing ligand enhances collagen production by human lung fibroblasts. Am J Respir Cell Mol Biol 28:225–231

    Article  PubMed  CAS  Google Scholar 

  31. Atamas SP, Yurovsky VV, Wise R, Wigley FM, Goter Robinson CJ, Henry P, Alms WJ, White B (1999) Production of type 2 cytokines by CD8+ lung cells is associated with greater decline in pulmonary function in patients with systemic sclerosis. Arthritis Rheum 42:1168–1178

    Article  PubMed  CAS  Google Scholar 

  32. Freiberg RA, Spencer DM, Choate KA, Duh HJ, Schreiber SL, Crabtree GR, Khavari PA (1997) Fas signal transduction triggers either proliferation or apoptosis in human fibroblasts. J Invest Dermatol 108:215–219

    Article  PubMed  CAS  Google Scholar 

  33. Chou AH, Tsai HF, Lin LL et al (2001) Enhanced proliferation and increased IFN-production in T cells by signal transduced through TNF-related apoptosis-inducing ligand. J Immunol 167:1347–1352

    PubMed  CAS  Google Scholar 

  34. Halaas O, Vik R, Ashkenazi A, Espevik T (2000) Lipopolysaccharide induces expression of APO2 ligand/TRAIL in human monocytes and macrophages. Scand J Immunol 51:244–250

    Article  PubMed  CAS  Google Scholar 

  35. Luzina I, Atamas S, Lockatell L, Rus V (2011) CCL18-mediated pulmonary infiltration of T lymphocytes is independent of TRAIL but requires DR5. J Immunol 186:102.20

    Google Scholar 

  36. Fries KM, Blieden T, Looney RJ et al (1994) Evidence of fibroblast heterogeneity and the role of fibroblast subpopulations in fibrosis. Clin Immunol Immunopathol 72:283–292

    Article  PubMed  CAS  Google Scholar 

Download references

Disclosures

None.

Author information

Authors and Affiliations

  1. Rheumatology and Rehabilitation Department, Faculty of medicine, Cairo University, Cairo, Egypt

    Noha A. Azab & Hanaa M. Rady

  2. Medical Biochemistry Department, Faculty of medicine, Cairo University, Cairo, Egypt

    Samar A. Marzouk

Authors
  1. Noha A. Azab
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hanaa M. Rady
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Samar A. Marzouk
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Noha A. Azab.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Azab, N.A., Rady, H.M. & Marzouk, S.A. Elevated serum TRAIL levels in scleroderma patients and its possible association with pulmonary involvement. Clin Rheumatol 31, 1359–1364 (2012). https://doi.org/10.1007/s10067-012-2023-3

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10067-012-2023-3

Keywords

Search

Navigation